benign|likely benign|conflicting interpretations of pathogenicity|uncertain significance|conflicting data from submitters
childhood|infancy
1-5 / 10 000
AllHighlyPenetrant; AT, COMPLEMENTATION GROUP C; Ataxia-telangiectasia; ATAXIA-TELANGIECTASIA, COMPLEMENTATION GROUP A; Ataxia-telangiectasia, complementation group D; Ataxia-telangiectasia, complementation group E; ATAXIA-TELANGIECTASIA, FRESNO VARIANT; Breast and ovarian cancer; Breast cancer, familial; Cancer breast; Cancer predisposition; Cerebello-oculocutaneous telangiectasia; Hereditary breast and ovarian cancer; Hereditary breast and ovarian cancer syndrome; Hereditary breast and ovarian cancer syndrome (HBOC); Hereditary breast and/or ovarian cancer syndrome; Hereditary breast cancer; Hereditary Cancer Syndrome; Hereditary neoplastic syndrome; Immunodeficiency with ataxia telangiectasia; Louis-Bar syndrome; Malignant breast neoplasm; Neoplastic Syndromes, Hereditary; none provided; RECLASSIFIED - ADRA2C POLYMORPHISM; RECLASSIFIED - ADRB1 POLYMORPHISM; Tumor predisposition